| Similar Articles |
|---|
 |
The Motley Fool
February 4, 2008
Brian Lawler |
Best International Stock: Novo Nordisk A quick summary of Danish drugmaker Novo Nordisk, the world's number one manufacturer of diabetes medications.   |
The Motley Fool
October 31, 2006
Brian Lawler |
Novo Nordisk Still Knows Sales There's more competition in diabetes care now, but the Danish pharmaceutical is thriving. Investors, take note. |
Pharmaceutical Executive
October 1, 2005 |
Changing Diabetes An interview with Novo Nordisk's president of U.S. operations Martin Soeters on how a nation that leads the world in diabetes research does such a poor job of treating it. Here, he offers some solutions. |
The Motley Fool
August 12, 2005
Stephen D. Simpson |
Novo Nordisk Perks Up This leading insulin company rebounds from a sluggish first quarter. For investors willing to buy and hold a stock for years, Novo Nordisk could still be an interesting play on a serious and growing disease market. |
The Motley Fool
January 31, 2007
Brian Lawler |
Novo Nordisk Knows Sales Growth Diabetes care leads the way for this Danish drugmaker. Investors willing to do a little extra financial sleuthing will find a pharmaceutical company that's the global leader in a rapidly growing health-care segment. |
Chemistry World
September 24, 2012
Andrew Turley |
$100m of diabetes R&D in China Danish drug maker Novo Nordisk has announced plans to invest $100 million in its R&D site in Beijing, China. The move will create 130 -- 200 new research jobs. |
The Motley Fool
January 28, 2005
Stephen D. Simpson |
An Understated Scandinavian The Danish pharmaceutical may not be quite cheap enough to be a true value, but investors looking for a solid growth stock should see what's new with Novo Nordisk. |
The Motley Fool
November 5, 2007
Brian Lawler |
Follow the Trend With Novo Nordisk The future is bright for Danish drugmaker Novo Nordisk. The worldwide leader in diabetes treatments turns in another good quarter. |
The Motley Fool
October 27, 2005
Stephen D. Simpson |
What's New With Novo? Novo Nordisk is a good play on diabetes, but will new drugs reduce the need for insulin? Investors, take note. |
The Motley Fool
January 27, 2006
Stephen D. Simpson |
Challenges Needle Novo Nordisk The insulin franchise is attractive, but under threat. Guidance for 2006 wasn't impressive and there are definite challenges ahead. Investors, take note. |
The Motley Fool
June 27, 2008
Brian Lawler |
This Drug Market Is Booming One therapeutic category seems to be expanding significantly faster than most of its peers, the one that helps the unfortunately burgeoning number of diabetics in the U.S. and worldwide. |
The Motley Fool
August 8, 2008
Brian Lawler |
Not Bad, Novo Nordisk The drugmaker's performance is better than its numbers suggest. |
The Motley Fool
November 24, 2010
Brian Orelli |
Profit From the United States of Diabetes Half the country could have an early form by 2020. |
The Motley Fool
October 31, 2008
Brian Orelli |
Disease Is Good for Novo Nordisk The Danish drugmaker is able to grow despite the Danish krone moving against the currencies that predominate its sales.. |
AskMen.com
April 29, 2001
Joshua Levine |
Do You Have Diabetes? Diabetes is not contagious; people cannot "catch" it from one another. However, certain factors can increase one's risk of developing the disease... |
Chemistry World
November 9, 2010
Andrew Turley |
Company snapshot: Novo Nordisk As the results for the third quarter of this year roll in, one pharma major - Danish company Novo Nordisk - seems to have done better than most with its diabetes medicines. |
The Motley Fool
August 21, 2007
Brian Orelli |
Sweet Phase 3 Data Although diabetes drugs have come under fire lately, insulin maker Novo Nordisk is moving full steam ahead with its newest drug to help fight type 2 diabetes. |
Chemistry World
June 16, 2014
Phillip Broadwith |
Novo Nordisk to create 6000 jobs by 2022 Danish insulin and diabetes specialist Novo Nordisk says it intends to employ 6000 more highly skilled workers within Denmark by 2022. Half of these new staff will work in R&D. |
The Motley Fool
June 24, 2008
Brian Orelli |
A Diabetes Drug Delivery Deal Several pharmaceutical companies compete to deliver a diabetes medication that can be taken orally or once-weekly. |
The Motley Fool
September 30, 2008
Brian Lawler |
Novo Nordisk Takes On All Comers Its diabetes franchise is about to get bigger. |
The Motley Fool
April 30, 2008
Brian Lawler |
A Dominating Danish Drugmaker Novo Nordisk turns in solid first-quarter financial numbers. |
Chemistry World
September 3, 2014
Phillip Broadwith |
Novo Nordisk quits inflammation R&D and cuts jobs Novo Nordisk is terminating its inflammatory disease R&D programs after the company's leading rheumatoid arthritis drug candidate failed in clinical trials. |
The Motley Fool
July 27, 2007
Rich Duprey |
Sniffing Out Bentley's New Patent To succeed in insulin therapy, the generic drugmaker must overcome patent expiration. Investors, take note. |
Nursing Management
January 2012
Lawrence et al. |
Type 2 Diabetes: Growing to Epic Proportions Affecting all age groups and all aspects of a person's life, diabetes is a major public health issue worldwide, requiring lifelong behavioral and lifestyle changes and support. |
The Motley Fool
April 28, 2005
Stephen D. Simpson |
Novo Nordisk Could Use a Boost Investors reacted badly to first-quarter results, but there's still a lot to like about the Danish pharmaceutical. |
The Motley Fool
January 16, 2008
Brian Lawler |
Another Inhalable Insulin Bites the Dust Novo Nordisk discontinues development of its troubled diabetes treatment and settles its patent infringement lawsuit against Pfizer. Investors, take note. |
The Motley Fool
January 31, 2007
Brian Lawler |
No Sickness for Amylin Sales of the drugmaker's type-2 diabetes drugs showed solid growth. Investors, take note. |
Pharmaceutical Executive
July 1, 2009
Megan Svensen |
Get Organized What community organizing can teach pharma marketers about building a brand. |
Managed Care
May 2006
Fadia T. Shaya & Deshpande |
New Treatment Approaches To Diabetes The goal of diabetes management is maintaining glycemic control while targeting quality of life improvements. |
American Family Physician
October 15, 2003
Gavin et al. |
Reducing Cardiovascular Disease Risk in Patients with Type 2 Diabetes By increasing patient awareness of the link between diabetes and heart disease, family physicians can encourage patients to take medications (including aspirin), stop smoking, lower blood pressure, and lower cholesterol and blood glucose levels. |
Managed Care
October 2000 |
Diabetes Cases Up 33 Percent In Just 8 Years In findings that are likely to have serious implications for treatment-costs, adult incidence of diabetes rose 33 percent from 1990 to 1998, according to the U.S. Centers for Disease Control... |
The Motley Fool
May 20, 2009
Brian Orelli |
Joining to Treat, and Beat, Diabetes Medical-device maker Medtronic and drugmaker Eli Lilly are teaming up to co-promote the companies' diabetes products to doctors and patients. |
The Motley Fool
October 2, 2009
Brian Orelli |
Warning! Potential Blockbuster Ahead It's a little early to call it, but it looks like Bristol-Myers Squibb and AstraZeneca have a potential blockbuster on their hands with their new diabetes drug. |
Pharmaceutical Executive
November 1, 2014
William Looney |
Dane in America Jesper Hoiland, Novo Nordisk's President for North America, assesses the challenges and opportunities during his first year at the helm of the diabetes franchise leader's biggest affiliate market. |
The Motley Fool
June 23, 2010
Brian Orelli |
Duo of Diabetes Drug Deals Make J&J Better Licensing deals add to Johnson & Johnson's diabetes franchise. |
The Motley Fool
July 19, 2007
Brian Orelli |
Head to the U.S. to Sue Your Neighbor Danish Novo Nordisk and French Sanofi-Aventis fight over insulin-delivery systems. Since the patent covers the U.S., the two companies will need to fight it out in U.S. courts. |
Managed Care
May 2006
Martin Sipkoff |
Health Plans Are Ill-Prepared for Looming Diabetes Epidemic The problem is outpacing insurers' resources and perhaps even their commitment. Can the chronic care model help? |
Managed Care
June 2007 |
Seventy Percent Surge In Diabetes Spending Spending on endocrine and diabetes therapies could surge nearly 70% in the next two years, according to research. Diabetes treatments were the second leading contributor in total dollars to prescription drug spending growth in 2006. |
The Motley Fool
July 8, 2008
Brian Lawler |
Blockbuster Drugs Bound for Extinction? One of the biggest classes of prescription drugs, those for diabetes treatments, faces tougher FDA standards. |
The Motley Fool
June 27, 2005
Stephen D. Simpson |
Sniffing Out a Possible Diabetes Blockbuster Inhaled insulin has been a Holy Grail of diabetes care. Will it live up to lofty expectations? Pfizer, Sanofi-Aventis, and Lilly are all interesting in their own right as high-quality pharmaceutical companies, and more aggressive investors should take a look at Nektar and Alkermes, as well. |
The Motley Fool
September 30, 2011
Brian Orelli |
A Drug Market That's 366 Million Strong Diabetes drugs have potential. |
The Motley Fool
June 30, 2011
David Williamson |
Biotech Takes On the Next Big Problem The news coming out of this week's annual conference of the American Diabetes Association wasn't good. |
The Motley Fool
January 26, 2010
Brian Orelli |
Is Victoza's Victory in Vain? Novo Nordisk finally gets the FDA to sign off on its once-daily diabetes drug. |
The Motley Fool
June 9, 2008
Brian Lawler |
Novo Nordisk's Daring Success Novo Nordisk's potential blockbuster compound excels in late-stage head-to-head testing. Investors, take note. |
HBS Working Knowledge
November 17, 2003
Martha Lagace |
The Business Case for Diabetes Disease Management Diabetes is a tough disease to tackle. A case-study discussion led by Harvard professor Nancy Beaulieu asked why it is so complex for business and society, and what might be done to curb its incidence. |
American Family Physician
November 1, 2000 |
Diabetes: How Do I Know if I Have it? Diabetes is a disease that occurs when your body doesn't make enough of a hormone called insulin, or if your body doesn't use insulin the right way. If left untreated, it may result in blindness, heart attacks, strokes, kidney failure and amputations... |
Pharmaceutical Executive
February 1, 2007
Iaquinto & Palmisano |
Medical Education: A Platform for Success By pumping the science behind a brand, pharmaceutical companies can garner early loyalist - before a drug even hits the market. |
The Motley Fool
February 28, 2007
Brian Lawler |
No Dice for Novo Novo Nordisk reports a failed clinical trial for one of its top drugs. Shares were down more than 5% on the news. |
American Family Physician
October 15, 2003 |
Diabetes and Heart Disease I have diabetes -- why should I worry about heart disease?... What are the ABCs of diabetes?... Where can I learn more about diabetes and heart disease?... What can I do to reduce my risk for heart disease? |
The Motley Fool
July 22, 2009
Brian Orelli |
The Blockbuster Around the Corner Amylin Pharmaceuticals' Byetta sales are improving, but is it enough? |
